Halia Therapeutics’ CEO, David Bearss, recently discussed the FDA’s Project Optimus in The Wall Street Journal. These new regulations pose significant challenges for smaller biopharma companies like Halia. They risk driving innovation overseas due to higher costs and longer timelines. Halia remains, however, committed to identifying the most effective, lowest doses in early trials to deliver safe and potent treatments to patients.
